<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03268876</url>
  </required_header>
  <id_info>
    <org_study_id>2017/941</org_study_id>
    <nct_id>NCT03268876</nct_id>
  </id_info>
  <brief_title>The INFLUENCE of Cytoreduction on PRO in EOC</brief_title>
  <acronym>INFLUENCE</acronym>
  <official_title>The INFLUENCE of Cytoreduction on Patient Reported Outcomes in Patients With Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on an improved understanding of how the extent of successful cytoreduction is&#xD;
      influenced both by inherent tumor biological characteristics as well as the aggressiveness of&#xD;
      the surgical approach this project aims to better define the value of cytoreduction and to&#xD;
      use the knowledge gained to develop more individualized therapy and follow-up. This will be&#xD;
      achieved through a translational biomedical research approach. Due to the research group's&#xD;
      traditions clinical phenotyping, biomarker identification, and clinical trials will be the&#xD;
      focus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will be recruited at their follow-up appointment after their surgery. At this&#xD;
      consultation the patient will be informed about the final diagnosis and extent of disease and&#xD;
      a plan for their further chemotherapeutic treatment will be developed. All patients will be&#xD;
      offered carboplatin AUC 5 and paclitaxel 175mg/m2 q3w for 6 cycles [+ bevacizumab 7.5mg/kg&#xD;
      q3w for 18 cycles in high-risk women of recurrence (IIIc not maximal debulked with a rest&#xD;
      tumor of &gt;1 cm2 and stage IV)]. In they fulfill the inclusion criteria and agree the inform&#xD;
      consent formula will be signed. During the screening period the study team will secure that&#xD;
      the necessary information needed is available and study specific test and analysis will be&#xD;
      undertaken. After inclusion the study specific consultations will be scheduled coinciding&#xD;
      with the patient regular appointments for treatment and follow-up. The patients will be&#xD;
      followed at predetermined time points (after finalizing the chemotherapy; and every 3 months&#xD;
      thereafter for 2 years).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Global Health Score</measure>
    <time_frame>2 years</time_frame>
    <description>Is there a relationship between QOL score and immunologic profiling in biological samples?</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Epithelial ovarial cancer</arm_group_label>
    <description>Patients primary treated with primary surgery for advanced epithelial ovarian cancer (&gt; stage IIa) at the participating institutions will be asked to participate.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine and tumor biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients primary treated with primary surgery for advanced epithelial ovarian cancer at the&#xD;
        participating institutions will be asked to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Epithelial ovarian cancer&#xD;
&#xD;
          -  Stage &gt; II&#xD;
&#xD;
          -  ECOG &lt; II&#xD;
&#xD;
          -  Treated with primary surgery followed by chemotherapy&#xD;
&#xD;
          -  Willing to participate and to sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years old&#xD;
&#xD;
          -  Borderline and non-epithelial ovarian tumors&#xD;
&#xD;
          -  Stage &lt; II&#xD;
&#xD;
          -  Advanced ovarian cancer submitted to neoadjuvant chemotherapy&#xD;
&#xD;
          -  ECOG 3-4&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe cardiopulmonary disease&#xD;
&#xD;
          -  Patients participating in QoL intervention studies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Line Bjørge, MD, PhD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse-Bergen HF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Line Bjørge, MD, PhD, MBA</last_name>
    <phone>+4755975000</phone>
    <email>line.bjorge@uib.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Grete Iversen, MD</last_name>
    <phone>+4755975000</phone>
    <email>gaiv@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Line Bjørge, MD, PhD</last_name>
      <phone>+4755975000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sørlandet sykehus HF</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>August 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epithelial ovarian cancer</keyword>
  <keyword>Surgery</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

